Search Results 221-230 of 16386 for dyslipidemia
It belongs to a group of drugs called calcium channel blocking agents. Diltiazem affects the movement of calcium into the cells of the heart and blood vessels.
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
The Clinical Core of the Center for Cell Signaling in Gastroenterology supports faculty research by facilitating access to human biospecimens through two ...
Teriflunomide is used to treat the relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active ...
Participation eligibility · Evidence of hepatic steatosis by imaging. · Metabolic risk factors (diabetes mellitus/impaired fasting glucose, dyslipidemia, ...
This research study is being done to help characterize cardiovascular disease and improve diagnostic tests. OBJECTIVES. To understand the pathogenesis, ...
Participants taking anti-diabetic, anti-obesity, or anti-dyslipidemic medications must have been on stable regimens for at least 3 months (12 weeks) (6 weeks ...
Heart disease is the leading cause of death in the U.S. African Americans are significantly affected by cardiovascular disease.
The purpose of this study is to validate novel echocardiographic parameters and algorithms to quantitatively evaluate right ventricular function in patients ...
The Cardiovascular Disease and Outcomes Research Program at Mayo Clinic uses epidemiology, randomized trials, electronic epidemiology and data science ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Their crucial work saves lives every day. Let Mayo Clinic researchers know they’re appreciated with a quick message.